StocksFundsScreenerSectorsWatchlists
ICUI

ICUI - ICU Medical Inc Stock Price, Fair Value and News

96.84USD+0.96 (+1.00%)Market Closed

Market Summary

ICUI
USD96.84+0.96
Market Closed
1.00%

ICUI Alerts

  • 2 major insider sales recently.

ICUI Stock Price

View Fullscreen

ICUI RSI Chart

ICUI Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

-78.06

Price/Sales (Trailing)

1.02

EV/EBITDA

51.83

Price/Free Cashflow

28.12

ICUI Price/Sales (Trailing)

ICUI Profitability

Operating Margin

32.96%

EBT Margin

-2.79%

Return on Equity

-1.4%

Return on Assets

-0.68%

Free Cashflow Yield

3.56%

ICUI Fundamentals

ICUI Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

1.7%

Rev. Growth (Qtr)

6.24%

ICUI Earnings

Earnings (TTM)

-29.7M

Earnings Growth (Yr)

-10.37%

Earnings Growth (Qtr)

-336.9%

Breaking Down ICUI Revenue

Last 7 days

-3.9%

Last 30 days

-3.3%

Last 90 days

0.7%

Trailing 12 Months

-45.0%

How does ICUI drawdown profile look like?

ICUI Financial Health

Current Ratio

2.53

Debt/Equity

0.75

Debt/Cashflow

0.1

ICUI Investor Care

Shares Dilution (1Y)

0.60%

Diluted EPS (TTM)

-1.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.3B2.3B2.2B2.3B
20221.5B1.8B2.0B2.3B
20211.3B1.3B1.3B1.3B
20201.3B1.3B1.3B1.3B
20191.4B1.3B1.3B1.3B
20181.4B1.4B1.4B1.4B
2017537.3M772.0M1.0B1.3B
2016350.0M363.0M374.1M379.4M
2015317.5M322.6M331.2M341.7M
2014312.6M312.7M307.3M309.3M
2013315.7M317.0M318.4M313.7M
2012306.2M305.7M310.7M316.9M
2011290.7M299.9M300.9M302.2M
2010238.4M253.6M275.1M283.0M
2009214.4M219.2M218.4M229.0M
2008192.3M196.4M200.6M204.7M
2007000188.1M

Tracking the Latest Insider Buys and Sells of ICU Medical Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 15, 2024
sanzone virginia ruth
sold (taxes)
-87,291
98.08
-890
vp, general counsel
Mar 15, 2024
jain vivek
sold (taxes)
-261,972
98.08
-2,671
chairman and ceo
Mar 15, 2024
woolson daniel
sold
-77,732
98.2715
-791
vp, gm-infusion capital
Mar 15, 2024
sousa ben
acquired
-
-
1,299
chief information officer
Mar 15, 2024
voigtlander christian b.
sold (taxes)
-174,582
98.08
-1,780
chief operating officer
Mar 15, 2024
sanzone virginia ruth
acquired
-
-
1,624
vp, general counsel
Mar 15, 2024
sousa ben
sold (taxes)
-45,411
98.08
-463
chief information officer
Mar 15, 2024
jain vivek
acquired
-
-
4,871
chairman and ceo
Mar 15, 2024
bonnell brian michael
acquired
-
-
3,247
chief financial officer
Mar 15, 2024
bonnell brian michael
sold (taxes)
-174,582
98.08
-1,780
chief financial officer

1–10 of 50

Which funds bought or sold ICUI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 17, 2024
NEW MEXICO EDUCATIONAL RETIREMENT BOARD
new
-
913,000
913,000
0.03%
Apr 12, 2024
FIRST FINANCIAL CORP /IN/
unchanged
-
1,516
21,464
0.01%
Apr 12, 2024
AdvisorNet Financial, Inc
added
900
973
1,073
-%
Apr 11, 2024
CENTRAL BANK & TRUST CO
unchanged
-
758
10,732
-%
Apr 10, 2024
Bruce G. Allen Investments, LLC
added
30.00
398
1,395
-%
Apr 09, 2024
MASSMUTUAL TRUST CO FSB/ADV
added
6.00
701
5,688
-%
Apr 09, 2024
MATHER GROUP, LLC.
new
-
2,693
2,693
-%
Apr 05, 2024
GAMMA Investing LLC
added
75.14
17,068
33,269
0.01%
Apr 05, 2024
CWM, LLC
added
11.94
11,000
69,000
-%
Apr 04, 2024
MOODY NATIONAL BANK TRUST DIVISION
unchanged
-
89,247
1,263,590
0.10%

1–10 of 45

Are Funds Buying or Selling ICUI?

Are funds buying ICUI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ICUI
No. of Funds

Unveiling ICU Medical Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 01, 2024
smiths group plc
6.9%
1,670,000
SC 13D/A
Feb 13, 2024
janus henderson group plc
10.8%
2,617,933
SC 13G/A
Feb 13, 2024
fuller & thaler asset management, inc.
6.10%
1,472,050
SC 13G
Feb 08, 2024
wellington management group llp
6.53%
1,575,456
SC 13G/A
Jan 24, 2024
blackrock inc.
10.6%
2,558,515
SC 13G/A
Jan 10, 2024
vanguard group inc
10.11%
2,440,729
SC 13G/A
Dec 11, 2023
t. rowe price investment management, inc.
4.9%
1,173,610
SC 13G/A
Dec 06, 2023
blackrock inc.
10.4%
2,503,520
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
10.1%
2,423,228
SC 13G/A
Feb 10, 2023
janus henderson group plc
10.7%
2,557,226
SC 13G/A

Recent SEC filings of ICU Medical Inc

View All Filings
Date Filed Form Type Document
Apr 02, 2024
ARS
ARS
Apr 02, 2024
DEF 14A
DEF 14A
Apr 02, 2024
DEFA14A
DEFA14A
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 18, 2024
4
Insider Trading
Mar 15, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to ICU Medical Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
183.7B
40.1B
-5.83% 1.66%
32.1
4.58
-8.12% -17.45%
67.1B
19.5B
-2.32% -8.43%
53.41
3.44
4.02% -22.04%
22.6B
3.9B
-4.99% -13.70%
50.69
5.84
3.42% 23.09%
20.1B
14.8B
-4.86% -7.71%
7.56
1.35
2.12% 209.17%
MID-CAP
9.1B
3.5B
-0.64% 16.68%
32.12
2.62
4.97% 18.89%
9.0B
12.3B
-5.34% -15.09%
21.69
0.73
-2.44% -22.68%
8.5B
2.7B
-12.68% -39.24%
-13.34
3.18
-4.68% 82.43%
6.3B
4.0B
-7.94% -25.15%
-46.81
1.59
1.10% 85.84%
3.4B
366.4M
-1.55% 17.10%
-564.74
9.35
33.86% 89.83%
2.3B
6.6B
-3.92% -2.28%
11.91
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
-5.32% -19.06%
-1.85
0.39
7.73% -1066.14%
381.5M
166.7M
1.82% -7.51%
-4.61
2.29
6.67% -456.34%
253.5M
324.0M
17.44% -27.90%
-1.32
0.78
-3.19% -337.41%
45.7M
52.3M
-25.42% -56.00%
-2.44
0.87
17.61% 19.28%
3.7M
3.7M
-14.97% 255.00%
-0.3
0.99
5.77% 8.23%

ICU Medical Inc News

Latest updates
Defense World35 hours ago
Simply Wall St09 Mar 202408:00 am
Seeking Alpha27 Feb 202408:00 am

ICU Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue6.2%588553549569578598561543341336322318320319303329316307312331340
Cost Of Revenue-100.0%-369357377-411393374-208198205-205197207-189208196206
Gross Profit-6.7%172184192192175186168169127128124113120114106121114119104135135
Operating Expenses14.1%18416119018317518716821110489.0089.0086.0093.0088.0087.0095.0096.0086.0078.00105144
  S&GA Expenses4.0%15514915115314315315915381.0075.0074.0072.0074.0071.0067.0072.0071.0066.0068.0073.0077.00
  R&D Expenses7.4%22.0021.0022.0020.0023.0023.0023.0024.0013.0012.0011.0011.0012.0010.0010.0011.0013.0012.0011.0013.0014.00
EBITDA Margin-43.1%0.03*0.05*0.14*0.13*0.13*0.19*0.18*0.17*0.17*0.17*0.16*0.15*---------
Interest Expenses-786.8%-16624.0024.0023.00-11218.0015.0013.001.000.000.000.000.001.001.000.000.000.000.000.000.00
Income Taxes-55.0%-19.53-12.60-12.93-3.58-5.91-8.10-9.38-16.733.007.006.003.004.001.002.004.000.006.005.002.00-5.13
Earnings Before Taxes100.0%--5.37-22.86-13.39--21.31-16.85-54.80-38.0035.0027.0030.0026.0021.0020.0021.0033.0028.0033.00-12.48
EBT Margin0.4%-0.03*-0.03*0.06*0.06*0.06*0.06*0.07*0.08*0.10*0.10*0.09*0.08*---------
Net Income-336.9%-17.157.00-9.93-9.81-15.54-13.21-7.47-38.0720.0031.0028.0024.0026.0025.0019.0017.0021.0027.0023.0031.00-7.35
Net Income Margin-5.3%-0.01*-0.01*-0.02*-0.02*-0.03*-0.02*0.00*0.03*0.08*0.08*0.08*0.07*---------
Free Cashflow347.9%61.0014.00-19.7627.00-23.31-18.37-85.82-24.9561.0062.0039.0037.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets0.0%4,3784,3774,4634,4714,5164,4504,5904,7471,8811,8391,8031,7651,7641,7301,8591,8171,6921,6381,6231,6131,585
  Current Assets0.2%1,2211,2191,2451,2131,2351,1991,1901,1741,0301,0119739289219001,0371,002882944930921927
    Cash Equivalents28.9%254197196221209244256329553519462424396351446420269316292296345
  Inventory-6.6%709760775748696625583536290292300300315322323312338344330322311
  Net PPE0.7%613609617624636656668674468458459459467456455456456444437433433
  Goodwill1.9%1,4721,4441,4641,4631,4491,3701,4211,52743.0033.0033.0033.0033.0033.0032.0031.0031.0011.0011.0011.0011.00
  Current Liabilities3.8%482464484462495489486494201185184180195185359357248255260238249
  Long Term Debt-100.0%-1,5891,6011,6121,6241,6301,6361,642-------------
    LT Debt, Current11.6%51.0046.0040.0035.0030.0024.0019.0014.00------150150-----
    LT Debt, Non Current-100.0%-1,5891,6011,6121,6241,6301,6361,642-------------
Shareholder's Equity1.2%2,1232,0982,1152,1002,0902,0132,0862,1791,6161,5901,5571,5211,5021,4521,4121,3761,3771,3401,3181,2831,264
  Retained Earnings-2.1%808825818828838853866874912892861832809783758739722701675652621
  Additional Paid-In Capital0.7%1,3661,3561,3451,3401,3311,3231,3101,306721711706702693683675666669660658660658
Shares Outstanding0.0%24.0024.0024.0024.0024.0024.0024.0024.0021.0021.0021.0021.00---------
Float---3,601-----------3,306---4,836--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations159.6%91,26935,161-1,47441,245-1,7112,309-61,385-1,34282,62178,83554,76251,32078,52675,48629,22139,51948,86450,79623,268-21,01049,933
  Share Based Compensation-2.4%10,68510,9479,7739,1587,4288,7437,76212,0928,1056,5336,6816,0225,3406,2655,4106,9395,7573,7236,2296,2096,249
Cashflow From Investing-25.1%-30,650-24,508-17,606-15,183-23,998-12,528-5,192-1,867,750-32,941-21,086-17,779-18,881-40,903-24,080-9,684-23,472-100,999-23,900-31,476-10,513-19,083
Cashflow From Financing-22.7%-7,849-6,396-5,897-15,837-10,3852,530-4,0301,648,917-15,2791,108301-3,0004,426-148,5885,736138,3863,33193.002,901-17,232-69.00

ICUI Income Statement

2023-12-31
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
REVENUES:   
Revenues$ 2,259,126$ 2,279,997$ 1,316,308
Cost of Goods Sold1,519,2531,582,236824,818
Gross profit739,873697,761491,490
OPERATING EXPENSES:   
Selling, general and administrative606,693608,345302,583
Research and development85,34492,98447,498
Restructuring, strategic transaction and integration expenses41,25871,42118,037
Change in fair value of contingent earn-out(16,247)(32,091)0
Contractsettlements00127
Total operating expenses717,048740,659368,245
Income from operations22,825(42,898)123,245
Interest (Expense) Income, Net(95,219)(66,375)1,982
OTHER EXPENSE, NET(5,905)(5,136)(2,041)
(Loss) Income before income taxes(78,299)(114,409)123,186
Benefit (Provision) for income taxes48,64440,123(20,051)
Net (Loss) Income$ (29,655)$ (74,286)$ 103,135
Basic$ (1.23)$ (3.11)$ 4.86
Diluted$ (1.23)$ (3.11)$ 4.74
WEIGHTED AVERAGE NUMBER OF SHARES   
Basic (in shares)24,09123,86821,206
Diluted (in shares)24,09123,86821,781

ICUI Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents$ 254,222$ 208,784
Short-term investment securities5014,224
TOTAL CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENT SECURITIES254,723213,008
Accounts receivable, net of allowance for doubtful accounts of $11,064 at December 31, 2023 and $8,530 at December 31, 2022161,566221,719
Inventories709,360696,009
Prepaid income taxes21,98315,528
Prepaid expenses and other current assets73,64088,932
Total current assets1,221,2721,235,196
PROPERTY, PLANT AND EQUIPMENT, net612,909636,113
Operating Lease, Right-of-Use Assets69,90974,864
Long-term Investment Securities0516
GOODWILL1,472,4461,449,258
INTANGIBLE ASSETS, net870,588982,766
Deferred Income Tax Assets37,29531,466
Other Assets94,020105,462
TOTAL ASSETS4,378,4394,515,641
CURRENT LIABILITIES:  
Accounts payable150,030215,902
Accrued liabilities268,215242,769
Current portion of long-term debt51,00029,688
Income tax payable7,7146,200
Contingent earn-out liability4,8790
Total current liabilities481,838494,559
Contingent earn-out liability, Noncurrent3,99125,572
Long-Term Debt1,577,7701,623,675
Other long-term Liabilities100,497114,104
Deferred Income Tax55,873126,007
Income Tax Liability35,06041,796
COMMITMENTS AND CONTINGENCIES00
STOCKHOLDERS' EQUITY:  
Convertible preferred stock, $1.00 par value Authorized-500 shares; Issued and outstanding - none00
Common stock, $0.10 par value - Authorized-80,000 shares; Issued 24,144 and 23,995 shares at December 31, 2023 and 2022, respectively, and outstanding 24,141 and 23,993 shares at December 31, 2023 and 2022, respectively.2,4142,399
Additional paid-in capital1,366,4931,331,249
Treasury Stock, at cost(262)(243)
Retained earnings807,846837,501
Accumulated other comprehensive loss(53,081)(80,978)
Total stockholders' equity2,123,4102,089,928
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$ 4,378,439$ 4,515,641
Common stock, shares outstanding24,141,00023,993,000
ICUI
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 brand; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; professional services; critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
 CEO
 WEBSITEicumed.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES14500

ICU Medical Inc Frequently Asked Questions


What is the ticker symbol for ICU Medical Inc? What does ICUI stand for in stocks?

ICUI is the stock ticker symbol of ICU Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ICU Medical Inc (ICUI)?

As of Wed Apr 17 2024, market cap of ICU Medical Inc is 2.31 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ICUI stock?

You can check ICUI's fair value in chart for subscribers.

What is the fair value of ICUI stock?

You can check ICUI's fair value in chart for subscribers. The fair value of ICU Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ICU Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ICUI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ICU Medical Inc a good stock to buy?

The fair value guage provides a quick view whether ICUI is over valued or under valued. Whether ICU Medical Inc is cheap or expensive depends on the assumptions which impact ICU Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ICUI.

What is ICU Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, ICUI's PE ratio (Price to Earnings) is -78.06 and Price to Sales (PS) ratio is 1.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ICUI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ICU Medical Inc's stock?

In the past 10 years, ICU Medical Inc has provided 0.055 (multiply by 100 for percentage) rate of return.